Cargando…

Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine

Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijesundara, Danushka K., Yeow, Arthur, McMillan, Christopher L.D., Choo, Jovin J.Y., Todorovic, Aleksandra, Mekonnen, Zelalem A., Masavuli, Makutiro G., Young, Paul R., Gowans, Eric J., Grubor-Bauk, Branka, Muller, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630652/
https://www.ncbi.nlm.nih.gov/pubmed/38028199
http://dx.doi.org/10.1016/j.omtn.2023.102056
_version_ 1785132196732862464
author Wijesundara, Danushka K.
Yeow, Arthur
McMillan, Christopher L.D.
Choo, Jovin J.Y.
Todorovic, Aleksandra
Mekonnen, Zelalem A.
Masavuli, Makutiro G.
Young, Paul R.
Gowans, Eric J.
Grubor-Bauk, Branka
Muller, David A.
author_facet Wijesundara, Danushka K.
Yeow, Arthur
McMillan, Christopher L.D.
Choo, Jovin J.Y.
Todorovic, Aleksandra
Mekonnen, Zelalem A.
Masavuli, Makutiro G.
Young, Paul R.
Gowans, Eric J.
Grubor-Bauk, Branka
Muller, David A.
author_sort Wijesundara, Danushka K.
collection PubMed
description Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encoding secreted non-structural protein 1 of ZIKV (pVAX-tpaNS1) to elicit rapid protection in a T cell-dependent manner in mice. In the current study, we evaluated the stability, efficacy, and immunogenicity of delivering this DNA vaccine into the skin using a clinically effective and proprietary high-density microarray patch (HD-MAP). Dry-coating of pVAX-tpaNS1 on the HD-MAP device resulted in no loss of vaccine stability at 40°C storage over the course of 28 days. Vaccination of mice (BALB/c) with the HD-MAP-coated pVAX-tpaNS1 elicited a robust anti-NS1 IgG response in both the cervicovaginal mucosa and systemically and afforded protection against live ZIKV challenge. Furthermore, the vaccination elicited a significantly higher magnitude and broader NS1-specific T helper and cytotoxic T cell response in vivo compared with traditional needle and syringe intradermal vaccination. Overall, the study highlights distinctive immunological advantages coupled with an excellent thermostability profile of using the HD-MAP device to deliver a novel ZIKV DNA vaccine.
format Online
Article
Text
id pubmed-10630652
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-106306522023-10-16 Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine Wijesundara, Danushka K. Yeow, Arthur McMillan, Christopher L.D. Choo, Jovin J.Y. Todorovic, Aleksandra Mekonnen, Zelalem A. Masavuli, Makutiro G. Young, Paul R. Gowans, Eric J. Grubor-Bauk, Branka Muller, David A. Mol Ther Nucleic Acids Original Article Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encoding secreted non-structural protein 1 of ZIKV (pVAX-tpaNS1) to elicit rapid protection in a T cell-dependent manner in mice. In the current study, we evaluated the stability, efficacy, and immunogenicity of delivering this DNA vaccine into the skin using a clinically effective and proprietary high-density microarray patch (HD-MAP). Dry-coating of pVAX-tpaNS1 on the HD-MAP device resulted in no loss of vaccine stability at 40°C storage over the course of 28 days. Vaccination of mice (BALB/c) with the HD-MAP-coated pVAX-tpaNS1 elicited a robust anti-NS1 IgG response in both the cervicovaginal mucosa and systemically and afforded protection against live ZIKV challenge. Furthermore, the vaccination elicited a significantly higher magnitude and broader NS1-specific T helper and cytotoxic T cell response in vivo compared with traditional needle and syringe intradermal vaccination. Overall, the study highlights distinctive immunological advantages coupled with an excellent thermostability profile of using the HD-MAP device to deliver a novel ZIKV DNA vaccine. American Society of Gene & Cell Therapy 2023-10-16 /pmc/articles/PMC10630652/ /pubmed/38028199 http://dx.doi.org/10.1016/j.omtn.2023.102056 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Wijesundara, Danushka K.
Yeow, Arthur
McMillan, Christopher L.D.
Choo, Jovin J.Y.
Todorovic, Aleksandra
Mekonnen, Zelalem A.
Masavuli, Makutiro G.
Young, Paul R.
Gowans, Eric J.
Grubor-Bauk, Branka
Muller, David A.
Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
title Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
title_full Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
title_fullStr Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
title_full_unstemmed Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
title_short Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
title_sort superior efficacy of a skin-applied microprojection device for delivering a novel zika dna vaccine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630652/
https://www.ncbi.nlm.nih.gov/pubmed/38028199
http://dx.doi.org/10.1016/j.omtn.2023.102056
work_keys_str_mv AT wijesundaradanushkak superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT yeowarthur superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT mcmillanchristopherld superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT choojovinjy superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT todorovicaleksandra superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT mekonnenzelalema superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT masavulimakutirog superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT youngpaulr superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT gowansericj superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT gruborbaukbranka superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine
AT mullerdavida superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine